key: cord-0754415-8h5n9ask
authors: Hayashi, Koken; Wada, Hideo; Shiraki, Katsuya; Makino, Katsutoshi
title: Immune Thrombocytopenia and Cerebral Hemorrhaging Associated with COVID-19
date: 2021-08-31
journal: Intern Med
DOI: 10.2169/internalmedicine.7541-21
sha: 09023ee132483b240e753cc34c388ce3569615ed
doc_id: 754415
cord_uid: 8h5n9ask

nan

A 70-year-old man was admitted due to SARS-CoV-19. Computed tomography (CT) revealed severe ground-glass opacity and fibrosis in both lung fields (Picture A). Three weeks after a positive COVID-19 polymerase chain reaction test, his platelet counts gradually dropped to a minimum of 3×10 9 /L, while other blood cell counts were normal. Immune thrombocytopenia (ITP) associated with COVID-19 was diagnosed by exclusion of other potential entities, such as drug-induced thrombocytopenia. High dose intravenous γ globulin (HDIVG) and glucocorticoids at 1 mg/kg/day were started (1), which led to an improvement in the platelet count to 100×10 9 /L within 1 week. However, his awareness declined further, and follow-up CT revealed multiple cerebral hemorrhaging on day 15 (Picture B, arrowhead).

We considered ITP in this patient to be a complication of COVID-19, especially since he was an elderly patient with severe disease (1) . Furthermore, late-occurring severe throm-bocytopenia that might lead to life-threatening bleeding and cerebral hemorrhaging has been previously reported (2) .

Immune thrombocytopenia secondary to COVID-19: a systematic review

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Mie Prefectural General Medical Center

Koken Hayashi, koken.19910513@gmail.com 2021 The Japanese Society of Internal Medicine